Assessment of aldehyde dehydrogenase in viable cells.
R J Jones, J P Barber, M S Vala...
https://pubmed.ncbi.nlm.nih.gov/7742535/Actively Recruiting
Led by Northside Hospital, Inc. · Updated on 2026-10-14
20
Participants Needed
1
Research Sites
52 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of starting immunosuppression earlier to reduce Cytokine Release Syndrome CRS in patients undergoing hematopoietic stem cell transplantation. This Phase 2 study focuses on patients receiving a mismatched haploidentical related donor transplant with post-transplant cyclophosphamide. The goal is to improve transplant outcomes by preventing CRS, a serious immune reaction after transplantation. Participants will receive a combination of drugs cyclophosphamide on days 3 and 4 after transplant, tacrolimus starting from day -1 continuing to either day 90 or day 180, and mycophenolate mofetil from day 0 to day 35 post-transplant. This regimen aims to provide early immunosuppression to reduce complications. The study observes a single group receiving this treatment without a comparison group. During the study, participants will be monitored for CRS occurrence and severity within 30 days after transplant, and for safety related to early immunosuppression up to one year. Evaluations include clinical assessments and laboratory tests to track immune response and organ function. The total participation spans up to one year, allowing researchers to gather detailed safety and efficacy data over time.
CONDITIONS
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
M
Melh Solh, MD
C
Caitlin Guzowski, MBA, MHA, CCRC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Northside Hospital, Inc.
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Investigational regimen | Standard GVHD prophylaxis |
|---|---|---|
| What it is | A single‑group regimen using tacrolimus plus mycophenolate mofetil and post‑transplant cyclophosphamide administered early after haploidentical stem cell transplant | A longstanding GVHD prophylaxis approach using a calcineurin inhibitor (such as tacrolimus or cyclosporine) combined with methotrexate |
| Role in trial | Evaluated as the single prophylaxis strategy in all enrolled participants | Not evaluated in this trial; included only for contextual comparison |
| Primary use | Prophylaxis to prevent graft‑versus‑host disease after haploidentical transplant | Standard regimen used to reduce risk of graft‑versus‑host disease post allogeneic transplant |
| How it is given or performed | Tacrolimus starting Day ‑1 and continuing to Day +90 or +180, MMF from Day 0 to Day +35, and cyclophosphamide on Days +3 and +4 after transplant | Calcineurin inhibitor typically started shortly before or at transplant and methotrexate given in multiple low doses during early post‑transplant period |
| Evidence status | Efficacy and safety under investigation; results not yet reported | Established effectiveness in reducing GVHD risk based on long clinical experience |
| Important limitations | Single‑arm design lacks direct control group and limits comparative conclusions | Not evaluated in this trial; external comparator may differ in supportive care or patient context |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 months
Participants receive cyclophosphamide on days +3 and +4, mycophenolate mofetil from day 0 to day +35, and tacrolimus starting day -1 continuing to day +90 or +180 after transplant as part of the study treatment.
Regular visits during treatment period
Duration - Up to 1 year
Participants are monitored for safety and occurrence of Cytokine Release Syndrome with evaluations continuing up to one year after transplant.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
R J Jones, J P Barber, M S Vala...
https://pubmed.ncbi.nlm.nih.gov/7742535/Ramzi Abboud, Fei Wan, Jacopo Mariotti...
https://pubmed.ncbi.nlm.nih.gov/34262142/H Mayumi, M Umesue, K Nomoto
https://pubmed.ncbi.nlm.nih.gov/8877390/Jerrica Tang, Ryan R Jensen, Baylee Bryan...
https://pubmed.ncbi.nlm.nih.gov/38281591/Melhem M Solh, Elizabeth Dickhaus, Scott R Solomon...
https://pubmed.ncbi.nlm.nih.gov/30953027/Patrizia Chiusolo, Gesine Bug, Attilio Olivieri...
https://pubmed.ncbi.nlm.nih.gov/29421292/Asad Bashey, Xu Zhang, Connie A Sizemore...
https://pubmed.ncbi.nlm.nih.gov/23423745/Ephraim J Fuchs
https://pubmed.ncbi.nlm.nih.gov/23233586/Ramzi Abboud, Jesse Keller, Michael Slade...
https://pubmed.ncbi.nlm.nih.gov/27318038/Annalisa Ruggeri, Myriam Labopin, Giorgia Battipaglia...
https://pubmed.ncbi.nlm.nih.gov/32645444/Northside Hospital, Inc.
Lead Sponsor